Actually, SGP has two of the best phase-3 assets in the entire drug/biotech industry: TRA, an antiplatelet drug for various cardiovascular indications; and Boceprevir, a protease inhibitor for HCV.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”